跳至主要内容
临床试验/NL-OMON51582
NL-OMON51582已完成4 期

The influence of having bariatric surgery on the pharmacokinetics, safety and efficacy of the novel non-nucleoside reverse transcriptase inhibitor doravirine (LABRADOR) - LABRADOR

Afdeling Apotheek0 个研究点目标入组 1 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
1

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • - hiv-infected
  • - Viral load suppressed , below 40 copy/ml for at least 6 months, blips are
  • - planned to have bariatric surgery (gastric bypass or Sleeve gastrectomy)
  • - Able to sign informed consent
  • - Age above or equal to 18 years
  • - Using doravirine for at least 4 weeks prior to bariatric surgery with no
  • detectable viral load

排除标准

  • - History or current evidence of any condition, therapy, laboratory abnormality
  • or other circumstance that might confound the results of the study or interfere
  • with the subject*s participation
  • - Requires or is anticipated to require any of the prohibited medications known
  • to contradict/interact with doravirine
  • - Has significant hypersensitivity or other contraindication to DOR
  • - Creatinine clearance below 40 ml/min
  • - Severe liver dysfunction (Diagnosed liver cirrhosis: Child-Pugh C)
  • - Pregnancy or planning to be pregnant during first 6 months post surgery.

研究者

发起方
Afdeling Apotheek

相似试验

The influence of having bariatric surgery on the... | 临床试验